Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 33 |
| Active Pipeline (Recruiting Now) | 5 (4) |
| Completed vs Stopped Early | 25 / 3 (9.1%) |
| Median Closed Actual Enrollment | 215 participants |
| Physical Hospital Site Disclosure | 25.4% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | 3 |
| Charité Universitätsmedizin Berlin | Berlin | 3 |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06624670 | A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum | Phase III | RECRUITING |
| NCT03886246 | Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous | Phase II | ACTIVE NOT RECRUITING |
| NCT05295732 | The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis | Phase III | COMPLETED |
| NCT04154293 | A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis | Phase II | COMPLETED |
| NCT03395132 | Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beiso | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the LEO Pharma Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.